TITLE:
Dobesilate for dry age-related macular degeneration
AUTHORS:
Pedro Cuevas, Luis A. Outeiriño, Carlos Azanza, Javier Angulo, Guillermo Giménez-Gallego
KEYWORDS:
Dry Age-Related Macular Degeneration; Fibroblast Growth Factor Inhibition; Intravitreal Dobesilate
JOURNAL NAME:
Journal of Biomedical Science and Engineering,
Vol.6 No.10B,
October
15,
2013
ABSTRACT: We have evaluated the effects of intravitreal dobesilate, a synthetic fibroblast growth factor inhibitor, in patients with dry age-related macular degeneration, an inflammatory-related retinal disease without available treatment up to date. 36 eyes from 36 patients with dry age-related macular degeneration were treated with a single intravitreal dobesilate injection. The end points were the improvement from baseline visual acuity and normalization of retinal histology at one month. Intravitreal dobesilate injection resulted in a significant improvement in functional and anatomical outcomes at one month after injection. Our results suggest that intravitreal dobesilate may increase the chance of visual acuity gain in dry age-related macular degeneration, even in cases with initial low vision. This study supports the findings of previously published case reports, regarding the short-term improvement in visual acuity by intravitreal dobesilate injection in different degenerative retinal diseases.